论文部分内容阅读
树突状细胞(DC)是功能最强的专职抗原呈递细胞,在抗肿瘤免疫方面发挥着重要的作用.以DC为基础的肿瘤疫苗的研究发展迅速,其中效果最好的是DC/肿瘤融合细胞疫苗——不仅具有DC的抗原呈递功能,也持续产生内源性抗原肽.DC/肿瘤融合细胞疫苗不仅在动物实验中进行了大量的研究,而且已经进入了Ⅰ/Ⅱ期临床试验,结果表明,融合细胞能有效地诱导肿瘤特异性T淋巴细胞反应,病人也能很好地耐受.就DC/肿瘤融合疫苗的研究进展进行综述,并对目前研究中存在的问题作了客观的分析.
Dendritic cells (DCs) are the most potent specialized antigen-presenting cells and play an important role in antitumor immunity. The research on DC-based tumor vaccines is developing rapidly, and the best one is DC / tumor fusion Cellular vaccine - not only has the antigen presenting function of DC, but also continuously produces endogenous antigenic peptides.DDC / tumor fusion cell vaccines have not only been extensively studied in animal experiments but also have entered phase I / II clinical trials, and as a result The results show that the fusion cells can effectively induce tumor-specific T lymphocyte reaction and the patients are well tolerated.The research progress of DC / tumor fusion vaccine is reviewed and the problems existing in the current study are objectively analyzed .